Curis expands emavusertib PCNSL response pool as TakeAim CLL enrolment accelerates
Curis reports updated emavusertib responses in PCNSL and faster CLL enrolment, while durability, safety and funding remain critical tests.
Pharma & Biotech
Pharma & Biotech
Eli Lilly targets first-line CLL with Jaypirca as BRUIN CLL-314 trends toward PFS benefit
Lilly’s Jaypirca met its Phase 3 target in CLL, matching Imbruvica on response rate and showing superior safety. Could this rewire frontline BTK therapy?